IFNG and neoplasm: To investigate whether the tracer dose impacts ICI outcomes, we followed CT26 tumor growth in ICI-treated BALB/c mice receiving 0 μg, 50 μg (the imaging dose), or 250 μg (a neutralizing dose) of cold anti-IFNγ antibody with a treatment scheme matching our imaging experiments (Figure 4A).